{
"id":"mk19_a_nr_t43",
"number":43,
"bookId":"nr",
"title":{
"__html":"Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"93991f",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 43. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_nr_t43"
}
]
},
"Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"353bd6",
"class":"col hd l",
"children":[
"Medication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d795fa",
"class":"col hd l",
"children":[
"Route of Administration"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8655c2",
"class":"col hd l",
"children":[
"Potential Adverse Effects"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d858fe",
"class":"col hd l",
"children":[
"Recommended Monitoring"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c81cc",
"class":"col hd l",
"children":[
"Pregnancy Category",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"38c71d",
"class":"cell txt l",
"children":[
"Interferon beta-1a (three formulations) and interferon beta-1b (two formulations)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f619f8",
"class":"cell txt l",
"children":[
"Intramuscular or subcutaneous injection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c8c2bd",
"class":"cell txt l",
"children":[
"Flu-like symptoms, fatigue, depression, increased spasticity, transaminitis, rare autoimmune hepatitis, and injection-site reactions"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd2b77",
"class":"cell txt l",
"children":[
"CBC and liver enzymes every 3-6 months"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d61f8",
"class":"cell txt l",
"children":[
"C"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f9ff69",
"class":"cell txt l",
"children":[
"Glatiramer acetate (three formulations)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1660b5",
"class":"cell txt l",
"children":[
"Subcutaneous injection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"27b255",
"class":"cell txt l",
"children":[
"Injection-site reactions, lipoatrophy of skin at injection sites, and rare systemic panic attackâ€“like syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d5ed6",
"class":"cell txt l",
"children":[
"B"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9fc3cb",
"class":"cell txt l",
"children":[
"Sphingosine-1-phosphate treatments (fingolimod, siponimod, ozanimod)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1dfec3",
"class":"cell txt l",
"children":[
"Oral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"39cf34",
"class":"cell txt l",
"children":[
"Transaminitis, lymphopenia, increased risk of serious herpesvirus infection, hypertension, bradycardia (usually only with the first dose), macular edema, basal cell carcinoma, PML, disability worsening after discontinuation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"df22de",
"class":"cell txt l",
"children":[
"Pretreatment cardiac screening (all), cardiac monitoring (for bradycardia) after administration of first dose (fingolimod only), ophthalmologic screening (for macular edema), liver enzymes, CBC monitoring (for excessive lymphopenia), yearly skin examination (for basal cell carcinoma). CYP2C9 genotype screening for siponimod dosing."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93c5ee",
"class":"cell txt l",
"children":[
"Fingolimod = C Siponimod and ozanimod = no assigned category; no adequate data in humans, but teratogenicity seen in laboratory animal testing."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93c289",
"class":"cell txt l",
"children":[
"Fumaric acid esters (dimethyl fumarate, diroximel fumarate, monomethyl fumarate)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1dfec3",
"class":"cell txt l",
"children":[
"Oral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"61cab7",
"class":"cell txt l",
"children":[
"Diarrhea, nausea, abdominal cramping, flushing, lymphopenia, PML"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f9cce3",
"class":"cell txt l",
"children":[
"Frequent monitoring of CBC in first 6 months after administration and then every 6 months thereafter"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d61f8",
"class":"cell txt l",
"children":[
"C"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef7c5d",
"class":"cell txt l",
"children":[
"Teriflunomide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1dfec3",
"class":"cell txt l",
"children":[
"Oral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f350ea",
"class":"cell txt l",
"children":[
"Alopecia, gastrointestinal distress, respiratory infections, transaminitis, lymphopenia, hypertension, and peripheral neuropathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f1b994",
"class":"cell txt l",
"children":[
"Monitoring of CBC for lymphopenia, liver enzymes, and blood pressure frequently in the first 6 months, every 6 months thereafter"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"02129b",
"class":"cell txt l",
"children":[
"X"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"53ddc3",
"class":"cell txt l",
"children":[
"Cladribine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1dfec3",
"class":"cell txt l",
"children":[
"Oral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d94cc",
"class":"cell txt l",
"children":[
"Black-box warnings for malignancies and teratogenicity, lymphopenia, infections, hematologic toxicity, graft-versus-host disease with blood transfusion, hepatotoxicity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eaaf2d",
"class":"cell txt l",
"children":[
"Cancer screening, CBC, exclusion of infections, administration of vaccinations and herpes prophylaxis when necessary"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff2bc3",
"class":"cell txt l",
"children":[
"No assigned category; contraindicated in females and males not planning to use contraception because of embryo-lethality and teratogenicity seen in laboratory animals"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2449bd",
"class":"cell txt l",
"children":[
"Natalizumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"361ee9",
"class":"cell txt l",
"children":[
"Intravenous"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e2ab43",
"class":"cell txt l",
"children":[
"Black-box warning of increased risk of PML, common adverse effects of headache and chest discomfort, and rare hepatotoxicity, infusion reactions, and anaphylactic reactions"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2aed90",
"class":"cell txt l",
"children":[
"Rigorous, regimented, industry-sponsored monitoring (TOUCH program) and JC virus antibody testing (both screening and intermittent monitoring)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d61f8",
"class":"cell txt l",
"children":[
"C"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fda758",
"class":"cell txt l",
"children":[
"Alemtuzumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"361ee9",
"class":"cell txt l",
"children":[
"Intravenous"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"555f1e",
"class":"cell txt l",
"children":[
"Infusion reactions (including anaphylaxis), infections (especially herpes virus and fungal), autoimmune thyroiditis, ITP, glomerular nephropathy, increased risk of dermatologic malignancy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"957740",
"class":"cell txt l",
"children":[
"Rigorous, regimented, industry-sponsored monitoring program (Lemtrada REMS); monthly CBC, serum creatinine measurement, and urinalysis; quarterly thyroid function for 48 months after first infusion; yearly skin examination"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d61f8",
"class":"cell txt l",
"children":[
"C"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5c5c97",
"class":"cell txt l",
"children":[
"Ocrelizumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"361ee9",
"class":"cell txt l",
"children":[
"Intravenous"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a5bc36",
"class":"cell txt l",
"children":[
"Allergic infusion reactions (such as urticaria, pruritus, anaphylaxis), infections (especially herpesvirus or hepatitis B virus reactivations); possible increased risks for PML and cancer"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a85df9",
"class":"cell txt l",
"children":[
"Preinfusion screening with CBC and hepatitis B serologies; consider preinfusion vaccinations (against, for example, herpes zoster, streptococcal pneumonia, hepatitis B)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"216e2c",
"class":"cell txt l",
"children":[
"No assigned category, with some risk seen in animal studies; contraception suggested for 6 months after each infusion"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c56a94",
"class":"cell txt l",
"children":[
"Ofatumumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2eb1e0",
"class":"cell txt l",
"children":[
"Subcutaneous"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"be3941",
"class":"cell txt l",
"children":[
"Injection site reactions, infections, reduced immunoglobulin levels"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6175ff",
"class":"cell txt l",
"children":[
"Screen for hepatitis B; consider vaccinations (against, for example, herpes zoster, streptococcal pneumonia, hepatitis B) before initiation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f611d6",
"class":"cell txt l",
"children":[
"No assigned category, with some risk seen in animal studies; contraception suggested and warnings for potential fetal harm"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aab984",
"class":"cell txt l",
"children":[
"Mitoxantrone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"361ee9",
"class":"cell txt l",
"children":[
"Intravenous"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1d6138",
"class":"cell txt l",
"children":[
"Black-box warnings for cardiotoxicity and acute myelogenous leukemia; other adverse effects of infection, nausea, oral sores, alopecia, menstrual irregularities, and blue discoloration of urine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a8b82",
"class":"cell txt l",
"children":[
"Required monitoring of cardiac function by echocardiography or multigated radionucleotide angiography before each infusion and regular CBC"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f623e7",
"class":"cell txt l",
"children":[
"D"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CBC = complete blood count; ITP = immune thrombocytopenic purpura; PML = progressive multifocal leukoencephalopathy; REMS = risk evaluation and migraine strategy."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Pregnancy categories: A, no disclosed fetal effects; B, animal studies failed to demonstrate fetal risk; C, animal studies suggest adverse fetal effects; D, evidence of human fetal risk; X = documented fetal abnormalities. The FDA is no longer using these letter categories for newly approved drugs; for prescription drugs that were previously approved, these changes will be phased in gradually."
]
]
}